Ascendis Pharma A (ASND) Operating Leases (2018 - 2025)

Ascendis Pharma A has reported Operating Leases for 8 years, with the latest figure at $136.4 million in Q3 2025.

• Quarterly Operating Leases rose 20.23% year-over-year to $136.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $136.4 million (up 20.23% YoY) and the FY2024 annual result came in at $99.4 million, up 8.63% from the prior year.
• Operating Leases climbed to $136.4 million in Q3 2025 per ASND's latest filing, from $117.1 million in the prior quarter.
• Over five years, Operating Leases peaked at $136.4 million in Q3 2025 and troughed at -$7.4 million in Q4 2021.
• A 5-year average of $66.1 million and a median of $98.7 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2024: Operating Leases sank 104.1% in 2022, then surged 2253.82% in 2024.
• Over 5 years, Operating Leases stood at -$7.4 million in 2021, then rose by 11.83% to -$6.5 million in 2022, then soared by 1503.68% to $91.0 million in 2023, then gained by 9.21% to $99.4 million in 2024, then soared by 37.19% to $136.4 million in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $136.4 million, $117.1 million, and $113.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.